cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.3hpcn6
title: Occurrence Download

description: A dataset containing 2357 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Danthonia californica Bol.",
 "Geometry POLYGON((-141 24, -53 24, -53 83, -141 83, -141 24))"
 ]
}

 The dataset includes 2357 records from 93 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017524-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.23yjbq
title: Occurrence Download

description: A dataset containing 2076 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Brazil",
 "OccurrenceStatus is Present",
 "TaxonKey is Iguana Laurenti, 1768"
 ]
}

 The dataset includes 2076 records from 49 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017525-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mjw54m
title: Occurrence Download

description: A dataset containing 103 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "Geometry POLYGON((121.22836 40.55153,122.26774 40.55153,122.26774 41.439,121.22836 41.439,121.22836 40.55153))",
 "HasGeospatialIssue is false",
 "TaxonKey is Fulica atra Linnaeus, 1758"
 ]
}

 The dataset includes 103 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017523-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hfw9ma
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mullus japonicus Houttuyn, 1782",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017527-241126133413365/datasets/export for details.
DOI: 10.15468/dl.tn8zjh
title: Occurrence Download

description: A dataset containing 109 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Odonata Central",
 "Geometry POLYGON((-82.35731 42.96593,-82.26404 42.96593,-82.26404 43.03486,-82.35731 43.03486,-82.35731 42.96593))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 109 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017529-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fa6rd2
title: Occurrence Download

description: A dataset containing 1364 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "StateProvince is New YOrk",
 "TaxonKey is Aeshna Fabricius, 1775"
 ]
}

 The dataset includes 1364 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017528-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.e5b3we
title: Occurrence Download

description: A dataset containing 2523144 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON((88.0233923685258 20.7904367131327, 92.631689894586 20.7904367131327, 92.631689894586 26.5715308700568, 88.0233923685258 26.5715308700568, 88.0233923685258 20.7904367131327))"
 ]
}

 The dataset includes 2523144 records from 496 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017492-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.nxtv6j
title: Occurrence Download

description: A dataset containing 69 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Ontario Breeding Bird Atlas 2001-2005",
 "Geometry POLYGON((-82.35731 42.96593,-82.26404 42.96593,-82.26404 43.03486,-82.35731 43.03486,-82.35731 42.96593))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 69 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017530-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25810/c862-0e81.79
title: US Television Coverage of Climate Change or Global Warming, 2000-2024 - October 2024

description: The Media and Climate Change Observatory Data monitors 130 sources (across newspapers, radio and TV) in 59 countries in seven different regions around the world. Data is assembled by accessing archives through the Lexis Nexis, Proquest and Factiva databases via the University of Colorado libraries. More information may be found at: http://mecco.colorado.edu.
DOI: 10.57702/j93xglyf
title: Tiergesundheitsinformationen für den Supply Chain Radar

description: EMPRES-i ist eine webbasierte Anwendung des Notfallpräventionsprogramms (EMPRES) der Ernährungs- und Landwirtschaftsorganisation der Vereinten Nationen (FAO). Diese Anwendung unterstützt veterinäre Dienste, indem sie den Zugang zu regionalen und globalen Tiergesundheitsinformationen erleichtert. Ziel ist es, die Früherkennung und schnelle Reaktion auf Tierseuchen zu fördern, um deren Ausbreitung zu verhindern und die Tiergesundheit weltweit zu verbessern.
DOI: 10.5281/zenodo.14277301
title: Starr et al., Supplemental data
DOI: 10.5281/zenodo.14277302
title: Starr et al., Supplemental data
DOI: 10.15468/dl.ajqpkb
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Arabis surculosa N.Terracc., Arabis nivalis Guss., Arabis surculosa A.Terracc., Arabis serpyllifolia subsp. nivalis (Guss.) B.M.G.Jones)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000"
 ]
}

 The dataset includes 2 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017531-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.azca3r
title: Occurrence Download

description: A dataset containing 632832 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is one of (FALSE)",
 "OccurrenceStatus is one of (Present)",
 "HasCoordinate is one of (TRUE)",
 "Geometry POLYGON ((-95.37011967075021 29.853041775975562, -95.38062274234781 29.85259384446291, -95.39102438349202 29.851254375741238, -95.40122415138313 29.849036305135442, -95.41112356859644 29.84596105153093, -95.42062708105041 29.842058308867816, -95.42964298662477 29.83736575717261, -95.43808432516023 29.831928696027045, -95.44586972100441 29.82579960414612, -95.45292416979477 29.819037629468763, -95.45917976178458 29.811708014846875, -95.46457633471056 29.803881465045066, -95.46906204996274 29.795633461328304, -95.47259388663659 29.787043530411115, -95.47513804891297 29.778194474967556, -95.47667028311491 29.76917157325047, -95.47717610171446 29.7600617556405, -95.47665091250411 29.7509527661372, -95.47510005208838 29.741932316916746, -95.47253872378614 29.73308724411251, -95.46899184095255 29.72450267292797, -95.46449377762117 29.716261200067066, -95.4590880292273 29.708442101268645, -95.45282678699164 29.701120571460997, -95.44577043031721 29.694367004714685, -95.4379869422744 29.688246320769796, -95.42955125391474 29.682817344452715, -95.42054452376145 29.678132243782212, -95.41105335937021 29.6742360320001, -95.40116898833313 29.671166138153364, -95.39098638651465 29.668952050208215, -95.38060337165435 29.667615033997407, -95.37011967075021 29.667167930596428, -95.3596359698461 29.667615033997407, -95.34925295498576 29.668952050208215, -95.3390703531673 29.671166138153364, -95.32918598213021 29.6742360320001, -95.31969481773899 29.678132243782212, -95.3106880875857 29.682817344452715, -95.30225239922602 29.688246320769796, -95.29446891118322 29.694367004714685, -95.2874125545088 29.701120571460997, -95.28115131227314 29.708442101268645, -95.27574556387927 29.716261200067066, -95.27124750054789 29.72450267292797, -95.26770061771428 29.73308724411251, -95.26513928941205 29.741932316916746, -95.2635884289963 29.7509527661372, -95.26306323978596 29.7600617556405, -95.26356905838551 29.76917157325047, -95.26510129258745 29.778194474967556, -95.26764545486385 29.787043530411115, -95.27117729153768 29.795633461328304, -95.27566300678987 29.803881465045066, -95.28105957971583 29.811708014846875, -95.28731517170567 29.819037629468763, -95.29436962049603 29.82579960414612, -95.3021550163402 29.831928696027045, -95.31059635487566 29.83736575717261, -95.31961226045 29.842058308867816, -95.32911577290398 29.84596105153093, -95.33901519011731 29.849036305135442, -95.34921495800842 29.851254375741238, -95.3596165991526 29.85259384446291, -95.37011967075021 29.853041775975562))",
 "Year is greater than or equal to 2008",
 "Year is less than or equal to 2024"
 ]
}

 The dataset includes 632832 records from 37 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017409-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ghae7j
title: Occurrence Download

description: A dataset containing 186 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is iNaturalist Research-grade Observations",
 "OccurrenceStatus is Present",
 "PublishingOrg is 28eb1a3f-1c15-4a95-931a-4af90ecb574d",
 "TaxonKey is Brillantaisia lamium (Nees) Benth."
 ]
}

 The dataset includes 186 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017532-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2wy8vh
title: Occurrence Download

description: A dataset containing 70 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pristipomoides sieboldii (Bleeker, 1855)",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 70 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017533-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00000258
title: A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus

description: This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.
DOI: 10.25934/pr00007686
title: A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus

description: Primary Objective:   -  To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives:   -  To compare a new formulation of insulin glargine and Lantus given in the morning or in the evening   -  To compare the incidence and frequency of hypoglycemic episodes   -  To assess the safety and tolerability of the new formulation of insulin glargine
DOI: 10.25934/pr00007731
title: 52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy

description: Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change in glycated hemoglobin A1c (HbA1c), from baseline to endpoint. Secondary objectives: Secondary study objectives are to compare the intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of blood glucose (BG) values (fasting, pre-/postprandial (ppBG), nocturnal, mean daily, fasting plasma glucose), daily BG profiles, BG and HbA1c response rates (predefined), hypoglycemic events, adverse events, change of late diabetes complications, weight, body-mass-index, course of total daily insulin dose and adjustment, blood lipid profile, microalbuminuria, standard lab and quality of life/treatment satisfaction.
DOI: 10.25934/pr00008189
title: A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial

description: The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.
DOI: 10.25934/00000642
title: A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.

description: The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women. A vaccine that prevents, or even reduces, the incidence of the common types of high-risk HPVs, particularly HPV-16 and HPV-18, could result in significant reduction in the incidence of cervical cancer and cancer-related mortality, as well as a reduction in the incidence of surgical procedures following abnormal Pap smears.
DOI: 10.25934/00000900
title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma

description: This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
DOI: 10.25934/00002245
title: A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD)

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008668
title: A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)

description: Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).
DOI: 10.25934/00001263
title: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of the Lp-PLA2 Inhibitor SB-480848 (40, 80mg od) on Carotid Plaque Composition in Patients With Carotid Artery Disease and Planned Carotid Endarterectomy, Stratified for Statin Use and Gender, After 14+/-4 Days Treatment

description: The primary objective is to determine Lp-PLA2 activity in atherosclerotic carotid plaques after 14 (+/-4) days treatment with darapladib, compared to placebo. Secondary objectives include determination of the change in Lp-PLA2 activity in blood, Lp-PLA2 mass in blood and plaque, specified biomarkers in blood and plaque and their respective correlation's with Lp-PLA2. In addition, the study aims to characterise the PK/PD of repeat oral doses of SB-480848, and safety and tolerability in this population.
DOI: 10.25934/00002396
title: A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation


description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00002980
title: A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis

description: The purpose of the study is to evaluate the effectiveness of adalimumab in combination with methotrexate compared to methotrexate alone on work disability in subjects with early rheumatoid arthritis
DOI: 10.25934/00003021
title: A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

description: A study to assess the safety and efficacy of adalimumab administered as a subcutaneous injection in adult Chinese subjects with rheumatoid arthritis and treated with methotrexate
DOI: 10.25934/00003074
title: A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

description: The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in combination with pegylated interferon/ribavirin (pegIFN/RBV) compared with pegIFN/RBV alone (ABT-267 placebo) in treatment naïve, hepatitis C virus (HCV), genotype 1-infected participants.
DOI: 10.25934/00003810
title: A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study

description: The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine. Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the consistency of consecutive vaccine lots and the non-inferiority of modified manufacturing processes of GlaxoSmithKline Biologicals HPV-16/18 vaccine and the vaccine safety, over 12 months, in young adolescents and women of 10-25 years of age at study start.
DOI: 10.25934/00004281
title: 204980: An Open-label Study to Evaluate the Correct Use of Placebo ELLIPTA™ Dry Powder Inhaler (DPI) Compared to Placebo Metered Dose Inhalers (MDI) in Subjects With Moderate Persistent Asthma

description: The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI relative to two metered dose inhalers (MDI), a GSK MDI and the AstraZeneca (AZ) MDI. It is a randomised, multi-centre, open-label, cross-over study comparing placebo ELLIPTA DPI with placebo MDI (GSK and AZ) to assess correct inhaler use. No active drug will be used in this study in order to prevent any drug-related effects. Approximately, 152 subjects will be randomized to receive ELLIPTA DPI inhaler and 152 will be randomized to receive one of the MDI inhalers, for use during the first period (P) (approximately 28 days). At Visit 2 (Day 28) all subjects previous receiving the ELLIPTA DPI will be randomized to receive one of the MDI inhalers and all subjects who received a MDI in the previous period will receive the ELLIPTA DPI for use during second period (approximately 28 days). Subjects will continue taking their asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period. ELLIPTA is a registered trademark of the GSK group of companies.
DOI: 10.25934/00004503
title: A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis

description: This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
DOI: 10.25934/00004819
title: A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia

description: The primary objective of this study is to evaluate the long-term safety and tolerability of paliperidone palmitate in Japanese patients with schizophrenia. Secondary objectives of this study are to: explore the efficacy on symptoms of schizophrenia and the maintenance of treatment effect; explore the pharmacokinetics of paliperidone palmitate through sparse pharmacokinetic sampling.
DOI: 10.25934/00006121
title: A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)

description: The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma